FDA sounds the alarm on Pfizer’s blockbuster Xeljanz after a high dose was linked to a higher death rate, blood clots
The FDA is sounding a formal warning about the potential safety hazard posed by a high dose of Pfizer’s blockbuster Xeljanz, taking a move that could put a serious crimp in its blockbuster sales revenue.
Their statement today includes:
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 118,000+ biopharma pros reading Endpoints daily — and it's free.